Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease (ACTOR)
This study has been terminated.
(recruitment)
Sponsor:
Qualissima
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Qualissima
ClinicalTrials.gov Identifier:
NCT01048229
First received: January 12, 2010
Last updated: May 25, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |